ClinicalTrials.gg
RecruitingNCT07185815Updated May 1, 2026

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

A Phase 1/2 interventional study of Cariprazine Depot and Cariprazine Depot in Schizophrenia, Bipolar I Disorder and Major Depressive Disorder, sponsored by Mapi Pharma Ltd.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Mapi Pharma Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Planned enrollment
23rd of 23
24 · median 129
Started
2025
the only one that year
Phase 1/2
Only one
of the 23
Registered
20th of 23
by date
Lead sponsor
1 of 23
Mapi Pharma Ltd.

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 23rd largest by planned enrollment, is the only one that started in 2025, is the only one in phase 1/2, and was the 20th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral Cariprazine.

03

Conditions studied

  • Schizophrenia
  • Bipolar I Disorder
  • Major Depressive Disorder

Keywords

  • Long acting injection
  • LAI
  • Subcutaneous
  • SC
  • Cariprazine
  • Cariprazine Depot
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects who meet diagnostic criteria for schizophrenia, bipolar I disorder or major depressive disorder (this inclusion criterion relates to cohorts 1 and 2 only).
  • Clinically stable subjects (with no evidence of deterioration and on a stable dose of oral antipsychotic or antidepressant medication(s) other than Cariprazine for at least 4 weeks, prior to screening), receiving antipsychotic/s or antidepressant/s other than oral Cariprazine and eligible for treatment with Cariprazine 3 mg/day, with CGI-S score of 1-4.
  • Men and women aged 18-64 years (inclusive).
  • (BMI) 18.5-35.
  • Able to sign an form.
  • Adult subjects with a current diagnosis of schizophrenia, who meet DSM-5-TR diagnostic criteria for schizophrenia, naïve to or treated with antipsychotics (this inclusion criterion relates to cohort 3 only).

Key Exclusion Criteria:

  • Subjects with schizophrenia with PANSS item scores of > 4 on any of the following: P4 Excitement/Hyperactivity; P6 Suspiciousness/persecution; P7 Hostility; G8 Uncooperativeness; G14 Poor impulse control.
  • Subjects with schizoaffective disorder, delirium, dementia, amnestic, or other cognitive disorders or severe personality disorders.
  • Use of an drug, and/or participation in clinical studies with an investigational product within 3 months prior to screening.
  • History or current cardiovascular or cerebrovascular disease.
  • History of seizures or conditions that lower the seizure threshold.
  • Use of concomitant administration of strong or moderate inhibitors.
  • Use of concomitant medication of strong or moderate CYP3A4 inducers is .
  • Subjects with Suicidal Thoughts and Behaviors or has a history of suicidal ideation in the past year, or made a suicide attempt in the past 5 years.
  • Subjects with a history of orthostatic hypotension and/or syncope.
  • Subjects clinically stable on any dose of oral Cariprazine or add-on treatment (cohorts 1-2 only).
  • Subjects with CGI-S score of 5-7.
  • Subjects previously treated with partial D2 agonists, aripiprazole and brexipiprazole, and suffered from akathisia.
  • For cohort 3 only: Subjects treated with oral Clozapine.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Drug: Cariprazine Depot

  • Experimental
    Cohort 2

    Drug: Cariprazine Depot

  • Experimental
    Cohort 3

    Drug: Cariprazine Depot MTD · Drug: Oral Cariprazine 3 mg/day

Interventions

  • DrugCariprazine Depot

    One single dose of 22 mg

  • DrugCariprazine Depot

    One single dose of 44 mg

  • DrugCariprazine Depot MTD

    Three monthly doses of MTD (maximum tolerated dose)

  • DrugOral Cariprazine 3 mg/day

    Drug page: Cariprazine

    Oral Cariprazine 3 mg/day for three months

06

What researchers measure

Primary outcomes

  1. Safety, rate of adverse events (AEs)

    Time frame: Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort

  2. Plasma concentration of cariprazine and its active metabolites (DCAR, DDCAR)

    Time frame: Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort

Secondary outcomes

  1. Tolerability - Incidence and severity of injection site reactions

    Time frame: Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort

  2. Efficacy - Cohort 3: Positive and Negative Symptom Score (PANSS)

    Time frame: Through study completion, up to 24 weeks for each subject in the 3rd cohort

  3. Efficacy - Cohort 3: Clinical Global Impression Scale (CGI)

    Time frame: Through study completion, up to 24 weeks for each subject in the 3rd cohort

07

Study locations

6 of 6 sites recruiting
  • Mapi Pharma Investigational Site IN-101
    Ahmedabad, 380008, India
    Recruiting
    • Clinical Research Center · Contact
  • Mapi Pharma Investigational Site IN-102
    Ahmedabad, 380016, India
    Recruiting
    • Clinical Research Center · Contact
  • Mapi Pharma Investigational Site IL-004
    Beersheba, 8461144, Israel
    Recruiting
    • Clinical Research Center · Contact
  • Mapi Pharma Investigational Site IL-003
    Ness Ziona, 741000, Israel
    Recruiting
    • Clinical Research Center · Contact
  • Mapi Pharma Investigational Site IL-005
    Ramat Gan, 56621, Israel
    Recruiting
    • Clinical Research Center · Contact
  • Mapi Pharma Investigational Site IL-001
    Tel Aviv, 6423906, Israel
    Recruiting
    • Clinical Research Center · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 18 phase 1/2 interventional studies under Schizophrenia, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 70. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 22, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 3, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185815
Lead sponsor
Mapi Pharma Ltd.
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Aug 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 3, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Mark Weiser, Prof.
Contact
CarD@mapi-pharma.com
97236973776

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion